Caption Management’s Theravance Biopharma TBPH Stock Holding History

Caption Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$2.24M	–	1533
2022 Q4	$2.24M	Sell	200,000 -10,000	-5%	-$105K	0.04%	532
2022 Q3	$2.13M	Buy	+210,000	New	+$1.97M	0.03%	621
2022 Q2	–	Sell	-15,000	Closed	-$143K	–	1819
2022 Q1	$143K	Buy	+15,000	New	+$147K	﹤0.01%	1307
2021 Q3	–	Sell	-15,000	Closed	-$217K	–	1798
2021 Q2	$217K	Sell	15,000 -15,000	-50%	-$282K	﹤0.01%	1168
2021 Q1	$611K	Buy	+30,000	New	+$570K	0.01%	770
2020 Q4	–	Sell	-30,000	Closed	-$443K	–	1234
2020 Q3	$443K	Buy	+30,000	New	+$562K	0.01%	795
2020 Q2	–	Sell	-12,500	Closed	-$289K	–	1172
2020 Q1	$289K	Buy	+12,500	New	+$313K	0.02%	647

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's TBPH Position: Q1 2026 in Review

Caption Management opened a new position in Theravance Biopharma (TBPH) in Q1 2026: 163,704 shares worth $2.66M. The stake represents 0.02% of the portfolio and ranks #741 among its holdings. This is a return to the name: Caption Management previously reported a position in TBPH as recently as Q4 2022.

Caption Management first reported a position in TBPH in Q1 2019 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Caption Management held 163,704 shares of Theravance Biopharma worth $2.66M as of Q1 2026.
Theravance Biopharma was a new Caption Management position in Q1 2026.
Theravance Biopharma made up 0.02% of Caption Management's portfolio in Q1 2026, its #741 holding.
Caption Management first reported a position in Theravance Biopharma in Q1 2019 and has held it in 8 quarters since.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.